BiomX (NYSEMKT:PHGE) Shares Up 154.4% – Here’s What Happened

Shares of BiomX Inc. (NYSEMKT:PHGE) rose 154.4% during trading on Tuesday . The company traded as high as $0.7762 and last traded at $1.88. Approximately 53,300 shares traded hands during trading, a decline of 85% from the average daily volume of 347,190 shares. The stock had previously closed at $0.7390.

Analyst Ratings Changes

Separately, HC Wainwright restated a “buy” rating on shares of BiomX in a research report on Tuesday, November 25th. One investment analyst has rated the stock with a Buy rating, Based on data from MarketBeat.com, BiomX currently has an average rating of “Buy” and a consensus price target of $399.00.

BiomX Price Performance

The company has a market capitalization of $2.87 million, a price-to-earnings ratio of -2.51 and a beta of 1.56. The company has a fifty day simple moving average of $5.41 and a two-hundred day simple moving average of $7.99. The company has a debt-to-equity ratio of 0.51, a quick ratio of 2.84 and a current ratio of 2.84.

Hedge Funds Weigh In On BiomX

Hedge funds have recently made changes to their positions in the business. Citadel Advisors LLC acquired a new position in BiomX during the 3rd quarter worth approximately $85,000. ADAR1 Capital Management LLC bought a new stake in shares of BiomX during the 1st quarter worth about $166,000. Allostery Investments LP lifted its stake in shares of BiomX by 46.1% in the 1st quarter. Allostery Investments LP now owns 940,629 shares of the company’s stock worth $523,000 after acquiring an additional 296,796 shares during the period. Alyeska Investment Group L.P. acquired a new stake in shares of BiomX in the 3rd quarter worth approximately $835,000. Finally, Nantahala Capital Management LLC boosted its holdings in shares of BiomX by 44.1% in the first quarter. Nantahala Capital Management LLC now owns 2,493,309 shares of the company’s stock valued at $1,386,000 after acquiring an additional 762,709 shares in the last quarter. Hedge funds and other institutional investors own 40.57% of the company’s stock.

About BiomX

BiomX Ltd. is a clinical-stage biotechnology company developing targeted bacteriophage therapies designed to modulate the human microbiome. The company’s proprietary platform combines computational analytics with phage biology to identify and engineer virus-based agents that selectively target disease-associated bacteria without disrupting beneficial microbial communities. Through this precision approach, BiomX aims to address unmet needs in gastrointestinal and dermatological disorders driven by microbial dysbiosis.

BiomX’s pipeline includes investigational products for conditions such as Crohn’s disease, ulcerative colitis and acne.